Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Initiates Phase 1 Clinical Study of MM-398 in Combination With Cyclophosphamide for Pediatric Solid Tumors

CAMBRIDGE, Mass., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398...
January 13, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack to Present Preclinical Data at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that preclinical data on an analysis of HER2, HER3 and heregulin levels in gastric and...
December 20, 2013 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack to Present at the 32nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 32nd Annual...
December 13, 2013 08:30 ET | Source: Merrimack Pharmaceuticals

Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positive Breast Cancer

CAMBRIDGE, Mass., Dec. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 clinical trial results for MM-302, a novel HER2-targeted liposomal doxorubicin...
December 06, 2013 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present Phase 1 Data on MM-302 in Patients With Advanced HER2-Positive Breast Cancer

CAMBRIDGE, Mass., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced...
December 04, 2013 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack to Present at the Oppenheimer 24th Annual Healthcare Conference

CAMBRIDGE, Mass., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Oppenheimer...
November 26, 2013 07:00 ET | Source: Merrimack Pharmaceuticals

Merrimack and Actavis Announce Nanotechnology Collaboration

CAMBRIDGE, Mass. and DUBLIN, Ireland, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to...
November 26, 2013 07:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals' MM-121 Demonstrates Positive Signal in Two Phase 2 ER/PR+ Breast Cancer Studies

Metastatic Breast Cancer Study Reinforces Biomarker Findings From Previously Reported MM-121 Study in Ovarian Cancer Neoadjuvant Breast Cancer Study Shows Favorable Comparison in pCR Rate...
November 07, 2013 07:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Provides Third Quarter 2013 Operating Update and Financial Results

CAMBRIDGE, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
November 05, 2013 16:41 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Updates Timing of Third Quarter 2013 Investor Conference Call

CAMBRIDGE, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2013 Investor Conference call at 8 a.m....